5th April, 2016 – Dr. John C. Lechleiter, chairman, president, and CEO, Eli Lilly and Company, announced today that the company is set to invest €35 million in delivering a new high-tech manufacturing facility at its Kinsale campus, using pioneering technology that has the potential to transform how medicines are made in the future.The project will apply “Continuous Manufacturing Technology” to carry out the development and commercialisation of a number of Lilly’s small molecule pipeline products that are currently undergoing late-stage clinical trials.
Read the full article here